IMMERVISION
17.9.2020 15:38:17 CEST | Business Wire | Press release
Immervision , the Montreal-based leader in wide-angle intelligent vision, introduces JOYCE , the first humanoid robot developed by the computer vision community to help machines gain human-like perception and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005563/en/
Watch the video: https://vimeo.com/458617443
The purpose of JOYCE is to further advance computer vision technologies by inviting the community to help JOYCE gain a better understanding of her environment by upgrading her optics, sensors and AI algorithms.
To support the realization of this complex task, Immervision is also unveiling the JOYCE Development Kit for engineers and AI developers. This “JOYCE IN A BOX” development kit is equipped with three ultra-wide-angle panomorph cameras calibrated to give 2D hemispheric, 3D stereoscopic hemispheric or full 360 x 360 spherical capture and viewing of the environment. It uses data-In-picture technology so that each of her video frames can be enriched with data from a wide array of sensors providing contextual information to AI and neural networks, computer vision and SLAM algorithms to help increase her visual perception.
Moreover, JOYCE will be streaming live so that people can, not only follow the evolution of her capabilities, but also look through her eyes while she travels around the world, skydives, visits a business conference or a computer vision lab.
JOYCE stems from the Immervision InnovationLab which mission is to accelerate the emergence of new innovative solutions and help build the next generation of intelligent vision systems for a wide range of industry devices.
“At Immervision, we strongly believe in the value of bringing together the computer vision community to break down the silos that are slowing the innovation cycle. Instead, let’s push forward the boundaries of machine perception through cross-pollination. We believe that JOYCE will help develop extremely innovative solutions to resolve complex industry challenges,” said Pascale Nini, President and CEO of Immervision.
Potential use cases include:
- Enhance the performance of smart home devices such as vacuum cleaners, lighting systems and home appliances.
- Improve optics technologies to ensure driver safety in assisted driving and autonomous cars.
- Improve fire fighters ability to detect people and objects over trees and see through smoke.
- Improve medical diagnostics to better identify cancer tumors or other conditions on a CT scan.
- Help identify early signs of crop diseases, and many more.
To follow JOYCE’s progress and collaboration within the community, visit her at JOYCE.VISION and follow her on her social channels.
About Immervision
Immervision enables intelligent vision in any device. Our Deep Seeing technology and renowned experts in wide-angle optical design and image processing enable smart devices with superhuman eyes to capture high quality visual and contextual data. We invent, customise and license wide-angle lenses and imaging software technology for AI, machine vision and user applications, from capture to display, in the mobile, automotive, robotics, security, and other industrial and consumer product industries. www.immervision.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tech Sales Forecast to Reach $1.4 Trillion in 2026, Even as 56% of Consumers Delay Purchases, NIQ Finds1.9.2026 09:00:00 CEST | Press release
Global study finds price-sensitive shoppers will still pay more when products deliver clear, lasting benefits Global sales of consumer technology and durable goods are forecast to reach $1.4 trillion in 2026, up 5.1% year over year, even as 56% of consumers say they have delayed a technology purchase because of price or while waiting for a discount, according to new research from NIQ (NYSE: NIQ), the Official Global Insights Partner of IFA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901758503/en/ The era of automatic tech & durables upgrades is over. Released ahead of IFA 2026, which kicks off in Berlin on Sept. 4, 2026, NIQ today released its annual “State of Tech & Durables” report. Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified examines how years of economic volatility have transformed technology purchasing behavior and what manufacturers and retailers must do to remain competitive. Key
Searchlight Capital Partners Announces Investment in Aderian Group1.9.2026 09:00:00 CEST | Press release
Partnership will support Aderian’s continued growth and expansion across the Nordic region Searchlight Capital Partners, L.P. ("Searchlight"), a leading global private investment firm, today announced an investment in Aderian Group ("Aderian" or the "Company"), a Nordic managed IT services provider serving more than 10,000 small and medium-sized enterprise ("SME") customers throughout Sweden and Norway. As part of the transaction, Aderian's management team will reinvest in the Company and remain meaningful shareholders alongside Searchlight, underscoring their continued commitment to Aderian's long-term growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901430715/en/ Aderian provides cloud, cybersecurity, AI and analytics, networking and modern workplace solutions. Since its founding in 2022, the Company has grown to approximately SEK 2.5 billion in revenue, with more than 850 employees and over 10,000 SME customers a
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities1.9.2026 09:00:00 CEST | Press release
New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer biotechnology and pharmaceutical companies an integrated workflow combining regio-selective antibody labeling, high-throughput testing in human-relevant three-dimensional models and quantitative imaging analysis. The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therape
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release
Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
